Finally, we also found that PDCD4 dysregulation in cancers like ACC may increase AF risk through immune modulation, suggesting that targeting PDCD4 could benefit both AF and ACC patients. The gene discussed is PDCD4; the disease is adrenal cortex carcinoma.